Med. Pro Praxi 2009; 6(3): 144-146

Alcoholic liver disease

doc. MUDr. Radan Brůha CSc, MUDr. Karel Dvořák, MUDr. Jaromír Petrtýl CSc, MUDr. Tomislav Švestka CSc
IV. interní klinika VFN a 1. LF UK, Praha

Chronic alcohol abuse leads to impairment of many organs – most frequent organ involved in chronic alcoholism is liver. Liver disease

mortality in western countries is directly connected with alcohol abuse. The risk of alcoholic liver disease (ALD) increases in individuals

consuming more than 30 g of alcohol per day. ALD could manifested as chronic disease (steatosis, steatohepatitis, fibrosis, cirrhosis) or

acute disorder (acute alcoholic hepatitis). While steatosis is benign disease, cirrhosis is linked with shortened survival. The severity of

cirrhosis depends on complications – portal hypertension with variceal bleeding, ascites or encephalopathy. Survival of patients with

advanced cirrhosis is 1–2 years. Severe alcoholic hepatitis has 50% mortality. Basic treatment manipulation at ALD is abstinence. No

medicament was proved to improve the course of chronic disease. In the treatment of severe acute alcoholic hepatitis corticosteroids

could be used. The treatment of cirrhosis is the same as for cirrhosis of different etiology. In patients with advanced cirrhosis liver transplantation

should be considered if abstinence is confirmed.

Keywords: alcohol, cirrhosis, fibrosis, steatohepatitis, steatosis.

Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brůha R, Dvořák K, Petrtýl J, Švestka T. Alcoholic liver disease. Med. praxi. 2009;6(3):144-146.
Download citation

References

  1. Sherlock S, Dooley J. Nemoci jater a žlučových cest. České vydání, Nadační fond ČHS, 2004, 703 stran.
  2. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: An update to 2002. J Hepatol 2007; 46: 827-839. Go to PubMed...
  3. Caballeria J. Epidemiological aspects of alcoholic liver disease. In: Rodes J, et al. Textbook of Hepatology, Blackwell Publishing, 2007: 1129-1134 s. Go to original source...
  4. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-850. Go to original source... Go to PubMed...
  5. Marugame T, Yamamoto S, Yoshimi I, et al. Patterns of alcohol drinking and all-cause mortality: results from a largescale population-based cohort study in Japan. Am J Epidemiol 2007; 165: 1039-1046. Go to original source... Go to PubMed...
  6. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol. Interactions, outcomes and implications. J Clin Gastroenterol 2003; 36: 242-252. Go to original source... Go to PubMed...
  7. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-111. Go to original source... Go to PubMed...
  8. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27: 44-54. Go to original source... Go to PubMed...
  9. Edenberg HJ, Dick DM, Xuei X, et al. Variations in GABRA2, encoding the alpha 2 subunit of the GABA (A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet 2004; 74: 705-714. Go to original source... Go to PubMed...
  10. Tsukamoto H. Conceptual importance of identifying alcoholic liver disease as a lifestyle disease. J Gastroenterol 2007; 42: 603-609. Go to original source... Go to PubMed...
  11. Donohue TM Jr. Alcohol-induced steatosis in liver cells. World J Gastroenterol 2007; 13: 4974-4978. Go to original source... Go to PubMed...
  12. Song Z, Zhou Z, Deaciuc I, et al. Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease. Hepatology 2008; 47: 867-879. Go to original source... Go to PubMed...
  13. Barrio E, Tome S, Rodriguez I, et al. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28: 131-136. Go to original source... Go to PubMed...
  14. Reeves HL, Burt AD, Wood S, et al. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996; 25: 677. Go to original source... Go to PubMed...
  15. Teli MR, Day CP, Burt AD, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987. Go to original source... Go to PubMed...
  16. Diehl AM. Liver disease in alcohol abusers: clinical perspective. Alcohol 2002; 27: 7-11. Go to original source... Go to PubMed...
  17. Dousa M, Zima T, Bruha R, Svestka T, Petrtyl J. Sensitivity and specificity of CDT in the evaluation of alcohol abuse in cirrhotic patients. Gut 2006; 55(suppl. 5): A307.
  18. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis - a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167-1178. Go to original source... Go to PubMed...
  19. Akriviadis E, Botla R, Briggs W, et al. Pentoxyfylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648. Go to original source... Go to PubMed...
  20. Ryska M, Trunecka P. Liver transplantation - present status worldwide and in the Czech Republic. Cas Lek Ces. 2003; 142: 717-726.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.